Harrow, Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2026, with the Securities and Exchange Commission on August 10, 2026, disclosing a net loss of $17,270,000 for the second quarter and $44,872,000 for the first six months of the year.

Key Highlights

  • Q2 net loss: The company reported a net loss of $17,270,000 for the three months ended June 30, 2026, compared to net income of $4,995,000 in the same period of 2025.
  • Q2 total revenues: Total revenues were $70,661,000 for Q2 2026, up from $63,742,000 in Q2 2025.
  • Six-month net loss: For the six months ended June 30, 2026, net loss was $44,872,000, compared to a net loss of $12,785,000 for the same period in 2025.
  • Notes payable increase: Notes payable, net, rose to $292,379,000 at June 30, 2026, from $243,184,000 at December 31, 2025.
  • Accumulated deficit: The accumulated deficit reached $201,396,000 at June 30, 2026, compared to $156,524,000 at December 31, 2025.
  • Cash position: Cash and cash equivalents were $83,889,000 at June 30, 2026, up from $72,927,000 at December 31, 2025.
  • Shares outstanding: As of August 6, 2026, there were 37,487,850 shares of common stock outstanding.

Harrow's Q2 2026 Financial Results: Revenue Growth Alongside Rising Costs

According to the filing, Harrow, Inc. (Nasdaq: HROW) reported total revenues of $70,661,000 for the three months ended June 30, 2026, driven primarily by net product sales of $70,571,000. This compares to total revenues of $63,742,000 in Q2 2025. Despite the revenue increase, the company reported a loss from operations of $11,007,000 in Q2 2026, a reversal from operating income of $11,409,000 in the same quarter of 2025.

The filing attributes the swing to higher operating expenses. Selling, general and administrative expenses rose to $53,298,000 in Q2 2026 from $33,235,000 in Q2 2025, and research and development expenses increased to $8,072,000 from $2,868,000 over the same period. Cost of sales also increased, reaching $20,298,000 in Q2 2026 versus $16,230,000 in Q2 2025, resulting in gross profit of $50,363,000 compared to $47,512,000 a year earlier.

On the balance sheet, the filing reports total assets of $416,816,000 at June 30, 2026, up from $399,482,000 at December 31, 2025. Total stockholders' equity declined to $14,845,000 from $52,091,000 over the same period, reflecting the net loss for the six-month period. Accrued rebates and copay assistance increased to $55,481,000 from $42,236,000 at year-end 2025. Stock-based compensation expense for the six months ended June 30, 2026 was $7,625,000, according to the filing.

What Was Disclosed

Harrow, Inc. disclosed unaudited condensed consolidated financial statements for the quarter and six months ended June 30, 2026, showing revenue growth year over year alongside a significant increase in operating expenses and a widening net loss compared to the prior-year period.